Abstracts Archive - Page 325 of 2425 - ACR Meeting Abstracts

Abstract Number: 1443 • ACR Convergence 2023
Vasculitis Associations Among Patients with Systemic Lupus Erythematous
Emily Cosentino¹, Mia Blanchard², Diane L. Kamen¹ and Jim Oates¹, ¹Medical University of South Carolina, Charleston, SC, ²Claremont Graduate University, Claremont, CA
Background/Purpose: Vasculitis is rare manifestation of systemic lupus erythematous (SLE) that often leads to increased morbidity and mortality. Vasculitis prevalence in SLE patients have ranged…
Abstract Number: 1342 • ACR Convergence 2023
The Delivery of the Super-repressor IκBα by Exosomes Has the Potential to Alleviate Inflammation Associated with Rheumatoid Arthritis
Ki-Jeong Park¹, Ji-Hyoun Kang¹, Hae-In Lee², Yu Jeong Lee¹, Moon-Ju Kim¹, So-Hee Ahn³, Jae-Kwang Yoo³, Chulhee Choi³ and Tae-jong Kim⁴, ¹Chonnam National University Hospital, Gwangju, South Korea, ²Chonnam National University, Gwangju, South Korea, ³ILIAS Biologics, Daejeon, South Korea, ⁴Department of Rheumatology, Chonnam National University Medical School and Hospital, Gwang-Ju, South Korea
Background/Purpose: Rheumatoid arthritis (RA) is a persistent inflammatory disease primarily affecting the diarthrodial joints. Nuclear factor-κB (NF-κB) is a family of inducible transcription factors responsible…
Abstract Number: 1165 • ACR Convergence 2023
Long-term Changes in Lung Function in Melanoma Differentiation-associated Protein 5 (MDA5) Antibody Positive Dermatomyositis Patients: Experience of a Single Center Longitudinal Cohort in North America
Jenice Cheah¹, Sangmee Bae², Tiffany De Leon², Yuna Lee¹ and Christina Charles-Schoeman³, ¹University of California Los Angeles, Los Angeles, CA, ²UCLA Rheumatology, Los Angeles, CA, ³UCLA Medical Center, Santa Monica, CA
Background/Purpose: Interstitial lung disease (ILD) associated with antibodies to melanoma differentiation-associated protein 5 (MDA5 ab) in patients with dermatomyositis (DM) has been associated with a…
Abstract Number: 1604 • ACR Convergence 2023
First and Recurrent Thrombosis Risk After 4,454 Patient-Years of Follow-Up: Prospective Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Jonathan Thaler¹, Yasaman Ahmadzadeh², Danieli Andrade³, leslie skeith⁴, Maria Tektonidou⁵, Savino Sciascia⁶, Vittorio Pengo⁷, Jose Pardos-Gea⁸, Guillermo Ruiz-Irastorza⁹, Chary Lopez-Pedrera¹⁰, H Michael Belmont¹¹, Kello Nina¹², Paul R. Fortin¹³, Denis WAHL¹⁴, Maria Gerosa¹⁵, Guilherme De Jesús¹⁶, Zhuoli Zhang¹⁷, Tatsuya Atsuma¹⁸, Maria Efthymiou¹⁹, D. Ware Branch²⁰, Laura Andreoli²¹, Esther Rodriguez almaraz²², Michelle Petri²³, Giulia Pazzola²⁴, Ricard Cervera²⁵, Bahar Artim Esen²⁶, Hui Shi²⁷, Jason Knight²⁷, Guillermo Pons-Estel²⁸, Rohan Willis²⁹, Ali Duarte-Garcia³⁰, Maria Laura Bertolaccini³¹, Hannah Cohen³², Doruk Erkan¹ and On Behalf Of APS ACTION³³, ¹Hospital for Special Surgery, New York, NY, ²Roger Williams Medical Center, Providence, RI, ³University of São Paulo, São Paulo, Brazil, ⁴University of Calgary, Calgary, AB, Canada, ⁵Joint Academic Rheumatology Program, First Department of Propedeutic and Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece, ⁶University of Turin, Torino, Italy, ⁷Department of Cardiac-Thoracic-Vascular Sciences and Public Health University of Padova, Padova, Italy, ⁸Vall d'Hebron University Hospital, Barcelona, Spain, ⁹Hospital Universitario Cruces, Barakaldo, Spain, ¹⁰IMIBIC - Reina Sofia Hospital, Córdoba, Spain, ¹¹NYU School of Medicine, New York, NY, ¹²Northwell Health, Brooklyn, NY, ¹³Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada, ¹⁴University of Lorraine, Nancy, France, ¹⁵University of Milan, Milano, Italy, ¹⁶Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ¹⁷Peking University First Hospital, Rheumatology and Immunology Department, Beijing, China, ¹⁸Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Sapporo, Japan, ¹⁹University College London, London, United Kingdom, ²⁰University of Utah, Salt Lake City, UT, ²¹University of Brescia, Brescia, Italy, ²²Hospital Universitario 12 de Octubre, Madrid, Spain, ²³Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ²⁴Azienda Ospedaliera Santa Maria Nuova di Reggio Emilia, Reggio Emilia, Italy, ²⁵Hospital Clínic de Barcelona, Barcelona, Spain, ²⁶Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²⁷University of Michigan, Ann Arbor, MI, ²⁸CREAR, Rosario, Argentina, ²⁹University of Texas Medical Branch, Galveston, TX, ³⁰Mayo Clinic, Rochester, MN, ³¹King's College London, London, United Kingdom, ³²University College London Hospitals NHS Foundation Trust, London, United Kingdom, ³³on behalf of APS ACTION, New York, NY
Background/Purpose: The APS ACTION Registry was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL)-positive patients with or…
Abstract Number: 1574 • ACR Convergence 2023
The Role of 18F-FDG PET/CT Scans in Takayasu Arteritis
Sahil Jain¹, Abdulrahman Khormi², Marcela Munoz-Urbano³, Shirish Sangle¹ and David D'Cruz⁴, ¹Louise Coote Lupus Unit, Guy's and St Thomas' Hospital NHS Foundation Trust, London, United Kingdom, ²Prince Sattam University Medical College, Al-Kharj, Saudi Arabia, ³Clínica Imbanaco, Cali, Colombia, ⁴Guy’s Hospital, Louise Coote Lupus Unit, London, United Kingdom
Background/Purpose: Takayasu arteritis (TA) is a large-vessel vasculitis which primarily affects the aorta and its main branches. Accurate assessment of disease activity has always been…
Abstract Number: 1583 • ACR Convergence 2023
Comparison of Two Dosing Schedules for Oral Methotrexate (Split-Dose versus Single-Dose) Once Weekly in Patients with Active Rheumatoid Arthritis: A Multicenter, Open Label, Parallel Group, Randomized Controlled Trial (SMART Study)
Chandra Bhushan Prasad¹, Varun Dhir², Ranjan Gupta³, Koshy Nithin Thomas⁴, Devarasetti phani kumar⁵, VENKATESH S PAI⁶, Avinash Jain⁷, Shankar Naidu⁸, Priya Saini⁸, Leishangthem Bidyalaxmi⁸, AASTHA KHULLAR⁸, Ramesh Manthri⁹, Shefali Sharma¹⁰, Aman Sharma¹¹, Amita Aggarwal⁴ and Sanjay Jain⁸, ¹Healthway Hospital, Goa, Zuarinagar, India, ²PGIMER, CHD, INDIA, Chandigarh, India, ³All India Institute of Medical Sciences, New Delhi, India, ⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ⁵Nizams Institute of Medical Sciences, Hyderabad, India, ⁶AIIMS RISHIKESH, Rishikesh, India, ⁷SMS Medical College, Lucknow, India, ⁸PGIMER, Chandigarh, India, ⁹Department of Clinical Immunology and Rheumatology, Nizams Institute of Medical Sciences, Hyderabad, India, ¹⁰PGIMER< Chandigarh, Chandigarh, India, ¹¹PGIMER, Chandigarh, India, Chandigarh, India
Background/Purpose: Methotrexate (MTX), the anchor drug for rheumatoid arthritis (RA), has limited bioavailability above an oral dose of 15 mg. Split-dose oral MTX (morning, evening…
Abstract Number: 1570 • ACR Convergence 2023
Prognostic Assessment of the 2022 ACR/EULAR Classification Criteria for Takayasu Arteritis: A Multi-centre International Study
Emma Rinaldi¹, Corrado Campochiaro², Roberto Padoan³, Chengappa Kavadichanda⁴, Augustine Jose⁴, Kritika Singh⁵, Luca Iorio³, Naomi Viapiana⁶, Upendra Rathore⁵, Elena Marina Baldissera⁶, Vikas Agarwal⁵, Lorenzo Dagna⁷, Durga P Misra⁵ and Alessandro Tomelleri⁸, ¹Vita-Salute San Raffaele University, Milan, Italy, ²IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Disease. Vita-Salute San Raffaele University, Milan, Italy, ³Department of Medicine DIMED, University of Padova, Padova, Italy, ⁴Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India, ⁵Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ⁶IRCCS San Raffaele Hospital, Milan, Italy, ⁷Ospedale San Raffaele, Milano, Italy, ⁸Unit of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Scientific Institute, Milano, Italy
Background/Purpose: The 2022 ACR/EULAR classification criteria for Takayasu arteritis (TAK) rely on a point-based clinical and imaging scoring system (from 0 to 22). The aim…
Abstract Number: 1568 • ACR Convergence 2023
Comparison of Methotrexate and Azathioprine as the First Steroid-Sparing Immunosuppressive Agent in Patients with Takayasu’s Arteritis
Sema Kaymaz-Tahra¹, Ozun Bayindir Tsechelidis², Burak Ince³, Ozlem Ozdemir Isik⁴, Muhammet Emin Kutu⁵, Ozlem Karakas⁶, Tuba Demirci Yildirim⁷, Zeliha Ademoglu⁸, Elif Durak Ediboglu⁹, Burcu Ceren Ekti Uludogan¹⁰, Can Ilgin¹¹, Sule Yasar Bilge¹², Timucin Kasifoğlu¹², Servet Akar⁹, Hakan Emmungil⁸, Fatos Onen¹³, Ahmet Omma⁶, Nilufer Alpay Kanitez¹⁴, Ayten Yazici⁴, Ayse Cefle¹⁵, Murat Inanç¹⁶, Kenan Aksu¹⁷, Gökhan Keser¹⁷, Haner Direskeneli¹⁸ and fatma Alibaz-Öner¹⁹, ¹Sancaktepe Prof Dr Ilhan Varank Training and Research Hospital, Istanbul, Turkey, ²Ottawa University, Ottawa, ON, Canada, ³Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey, ⁴Kocaeli University Faculty of Medicine, Kocaeli, Turkey, ⁵Bakırkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey, ⁶Ankara City Hospital, Ankara, Turkey, ⁷Dokuz Eylul University, Izmir, Turkey, ⁸Trakya University Faculty of Medicine, Edirne, Turkey, ⁹Katip Celebi University Faculty of Medicine, Izmir, Turkey, ¹⁰Osmangazi University Faculty of Medicine, Eskişehir, Turkey, ¹¹Marmara University Faculty of Medicine, Istanbul, Turkey, ¹²Division of Rheumatology, Medical School, Osmangazi University, Eskişehir, Turkey, ¹³Division of Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey, ¹⁴Koc University Faculty of Medicine, Istanbul, Turkey, ¹⁵Division of Rheumatology, Medical School, Kocaeli University, Kocaeli, Turkey, ¹⁶Istanbul University, Istanbul, Turkey, ¹⁷Division of Rheumatology, Medical School, Ege University, Izmir, Turkey, ¹⁸Division of Rheumatology, Medical School, Marmara University, Istanbul, Turkey, ¹⁹Marmara University, School of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: Conventional disease-modifying anti-rheumatic drugs (cDMARDs) are recommended in addition to glucocorticoids (GC) for all active Takayasu's arteritis (TAK) patients as the first-line therapy. However,…
Abstract Number: 1590 • ACR Convergence 2023
Autoimmune Pathway Blockade by a Potent Orally Bioavailable STING Antagonist
Min Yang¹, Hailong Li¹, yangyang liu¹, lili yao¹, Jing Lin¹, Zhi xie² and Wenge zhong¹, ¹Regor Therapeutics, Shanghai, China, ²Regor Pharmaceuticals, Inc., San Francisco, CA
Background/Purpose: The cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway has emerged as a key innate immune mediator of autoimmune and inflammatory diseases. However,…
Abstract Number: 1592 • ACR Convergence 2023
Memantine Attenuates the Development of Osteoarthritis by Blocking NMDA Receptor Mediated Calcium Overload and Chondrocyte Senescence
Ning Wang¹, Qingmei Cheng¹, Xiaoxiao Li², ke he¹, Junyu Zhu¹, Hui Li³ and Jie Wei⁴, ¹中南大学湘雅医院, Changsha, China, ²Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University, Changsha, China, ³Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China, ⁴Health Management Center, Xiangya Hospital Central South University, Changsha, China
Background/Purpose: Memantine is an FDA proved drug utilized for the treatment of dementia and exerts its function by blocking the NMDA (N-methyl-D-aspartate) receptor, a calcium…
Abstract Number: 1561 • ACR Convergence 2023
Clinical Features and Quality of Life of Japanese Bechet’s Disease Patients with Arthritis: A Japanese Monocentric Study
Koichi Sugihara¹, Risa Wakiya², Yusuke Ushio³, Shusaku Nakashima², Hiromi Shimada², Taichi Miyagi⁴, Kanako Chujo⁵, Ryoko Kagawa³, Hayamasa Yamaguchi³, Tomohiro Kameda² and Hiroaki Dobashi⁶, ¹Kagawa University, Miki-cho, Kita-gun, Japan, ²Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan, ³Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan, ⁴Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kidagun, Japan, ⁵Kagawa University, Miki, Kita District, Kagawa, Japan, ⁶Kagawa University, Kagawa, Japan
Background/Purpose: Arthritis is positioned as one of the main symptoms in Behcet's disease (BD), and it is a relatively frequent symptom that is observed in…
Abstract Number: 1556 • ACR Convergence 2023
Abdominal Surgical Interventions Among Patients with Gastrointestinal Involvement of Behçet Syndrome
Sinem Nihal Esatoglu¹, Sabriye Guner¹, Sevim Guler², Gulen Hatemi¹, Nuray Kepil³, Yusuf Ziya Erzin⁴, Aykut Ferhat Celik⁴ and Ibrahim Hatemi⁴, ¹Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Istanbul, Turkey, ³Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Pathology, Istanbul, Turkey, ⁴Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey
Background/Purpose: Gastrointestinal involvement of Behçet's syndrome (GIBS) may require surgery in up to one third of the patients. We aimed to investigate the clinical characteristics,…
Abstract Number: 1588 • ACR Convergence 2023
Monocyte-derived Macrophages Accumulate in the Lungs in anti-MDA5+ Dermatomyositis with RP-ILD: Proinflammatory and Profibrotic Phenotype Revealed by Single-cell RNA Sequencing
Xiaoya Pei¹, Jia Shi², Yangzhong Zhou², Xiao Zhang², Xiaoman Wang¹, Mingwei Tang², Shuang Zhou², chanyuan wu², Jinmin Peng³, Mengtao Li⁴, xiaofeng Zeng², Jun Liu⁵, Houzao Chen¹ and Qian Wang², ¹State Key Laboratory of Medical Molecular Biology, Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ²Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ³Medical Intensive Care Unit, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China, ⁴Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁵State Key Laboratory of Protein and Plant Gene Research, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, China
Background/Purpose: Anti-melanoma differentiation-associated gene 5-positive dermatomyositis (anti-MDA5+ DM) is a rare inflammatory autoimmune disease with impressively life-threatening rapid progressive interstitial lung disease (RP-ILD). The mechanism…
Abstract Number: 1128 • ACR Convergence 2023
Refractory Inflammatory Ocular Pathology and Treatment with Janus Kinase Inhibitors. Multicenter Study and Literature Review
Carmen Lasa-Teja¹, Lara Sanchez-Bilbao², Jose Luis Martin-Varillas³, Vanesa Calvo Río⁴, José Luis Álvarez-Vega⁵, Emma Beltran-Catalan⁶, María del Mar Esteban-Ortega⁷, Santiago Muñoz⁷, Olga Maiz⁸, Ignacio Torre-Salaberri⁹, Ana Urruticoechea¹⁰, Elia Valls-Pascual¹¹, Raúl Veroz¹², Carmen Alvarez Reguera¹³, Rosalía Demetrio¹³ and Ricardo Blanco¹⁴, ¹Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology Group, Santander, Spain, ²Hospital Universitario Marques de Valdecilla, Santander, Spain, ³Hospital de Laredo, Laredo, Spain, ⁴Valdecilla Hospital, Santander, Spain, ⁵Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ⁶HOSPITAL DEL MAR, Barcelona, Spain, ⁷Hospital Infanta Sofia, Madrid, Spain, ⁸Hospital Universitario de Donostia. San Sebastián, Spain., Donosti, Spain, ⁹Hospital Universitario de Basurto, Bilbao, Spain, ¹⁰Hospital Can Misses, Ibiza, Spain, ¹¹Hospital Universitario Doctor Peset. Alicante, Spain., Valencia, Spain, ¹²Hospital de Mérida, Mérida. Spain., Mérida, Spain, ¹³Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Inflammatory ocular pathology (IOP) includes internal (uveitis) and external [mainly ocular surface pathology such as epi/scleritis and peripheral ulcerative keratitis (PUK)] involvement. IOP may…
Abstract Number: 1645 • ACR Convergence 2023
Aortic Dilatation and PET/CT Vascular Activity at Diagnosis and 5 Years in an Inception Giant Cell Arteritis (GCA) Cohort
Anthony Sammel¹, Ivan Ho Shon², Daniel Moses¹, Fredericks Stacey¹, Gita Mathur¹, Claudia Hillenbrand³, Edward Hsiao⁴, Schembri Geoffrey⁴, Rodger Laurent⁴ and Eva Wegner², ¹Prince of Wales Hospital, Randwick, Australia, ²The Prince of Wales Hospital, Sydney, Australia, ³University of NSW, Randwick, Australia, ⁴Royal North Shore Hospital, St. Leonards, Australia
Background/Purpose: Aortic dilatation is typically a late complication of giant cell arteritis (GCA) but there are no tools to risk stratify patients at the time…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].